Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and an...

Descripción completa

Detalles Bibliográficos
Autores principales: van Meerbeeck, J., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H., Pinson, P., van Glabbeke, M., van Marck, E., Giaccone, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/
https://www.ncbi.nlm.nih.gov/pubmed/8826866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/
https://www.ncbi.nlm.nih.gov/pubmed/8826866

Ejemplares similares